Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for BHC, they are:
In the past 5.52 years, Bausch Health Companies Inc has a compound free cash flow growth rate of -0.17%; that's better than just 8.96% of cash flow producing equities in the Healthcare sector, where it is classified.
28% of the company's capital comes from equity, which is greater than only 7.86% of stocks in our cash flow based forecasting set.
Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.3. This coverage rate is greater than that of only 24.31% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BHC, try EW, SRDX, COO, RHE, and OSMT.
LAUSANNE, Switzerland, Jan. 25, 2021 /CNW/ -- Tetra Pak has introduced a new collaborative innovation model with leading paperboard producers, a move aimed at tackling the food packaging industry's sustainability challenges.
Piper Sandler has downgraded to Bausch Health (BHC) to neutral from overweight questioning the cashflow resilience of the company’s pharmaceutical business.The analysts led by David Amsellem have however raised the price target to ~$30 from $25. Bausch shares are trading ~0.5% higher today.Announced in August, the diversified pharmaceutical unit of Bausch was...
Bausch Health (BHC) unit, Bausch + Lomb announces that Lumify (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval in South Korea. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea.